Something Different

Where’s the innovation? / Indian Priority Pathogen List / DTR video explainer

Dear All, Three things briefly this evening: First, the observation about the limited degree of innovation across products in Phases 1-3 in the recent newsletter about the Pew Pipeline review (only 1 in 4 are novel classes or novel mechanisms; none are potentially active against Gram-negative ESKAPE pathogens or WHO critical threat pathogens) generated queries along

Read More »

Stewardship & Access Guide from CARB-X, Wellcome, and partners: Analysis, video chat

Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The State of the World’s Antibiotics in 2021” makes this very clear: “… more people in LMICs (low-middle-income countries) die from lack of access to antimicrobials than from resistant infection.” Hence, CARB-X has

Read More »

Excellent Coronavirus Vaccine Q&A with Tony Fauci from JAMA Network

Dear All, Howard Bauchner, the editor-in-chief of JAMA, regularly does 30-minute Q&A podcasts. Today’s Q&A was with Tony Fauci and is a superb review of current state of play. Yes, he is ready to get the vaccine and is going to be vaccinated in public! Go here to listen. For more, below my signature you

Read More »

Movies to discover antibiotics by!

Dear All, Well, I think we can all agree that being grounded and shut away by COVID-19 is not exactly what any of us had in mind this spring! I certainly miss seeing everyone at the various events and I hope you are all keeping safe.  But, staying home does offer a bit of time

Read More »

Brilliant 5-minute video explainer of the AMR problem!

 Dear All, Andrew Jack of the Financial Times (FT) has produced a superb 5-minute video explainer of the AMR challenge! Featuring cameos from Kevin Outterson (CARB-X), Christine Ardal (Norwegian Institute of Public Health), and Manica Balasegaram (GARDP), the video deftly illustrates the economic challenge, the way that delinked Netflix-like models provide a solution, and the

Read More »

AMR Action Fund ($1b for P2-3): Video chat with new CEO! New committed funds!

Dear All, I’ve written before about the AMR Action Fund (9 Jul 2020 newsletter): In brief, it is ~$1b pledged by over 20 leading pharmaceutical companies to support the Phase 2-3 studies needed to bring 2-4 new antibiotics to approval by 2030 Stated differently, the AMR Action Fund provides Push incentives for Phase 2-3 to complement the Push Incentives

Read More »

FDA-NIAID phage workshop / Social distancing in the 1800s

Dear All, This webinar merits a standalone newsletter! If you are thinking (or working on) phage, then please mark your calendar for an FDA (CBER; Center for Biologics Evaluation and Research) workshop entitled: Science and Regulation of Bacteriophage Therapy: August 30, 2021—September 1, 2021 The purpose of the public workshop is to exchange information with the

Read More »

Useful AMR graphics: Poirel 2017 and Marston 2016

Dear All: There’s a very comprehensive review of the polymyxins by Poirel, Jayol, and Nordmann just out in Clin Micro Reviews (https://journals.asm.org/doi/10.1128/CMR.00064-16). If you’re a fan of good quality graphics as way to tell the story of AMR, their Figure 4 is worth capturing! Ditto their Figure 5 of outbreaks of colistin-resistant, carbapenemase-producing K. pneumoniae.

Read More »
Scroll to Top